Mariam Ahmed

MIT Department: Chemical Engineering

Undergraduate Institution: University of California, San Diego

Faculty Mentor: Paula Hammond

Research Supervisor: Santi Correa, Tony Barberio



I am a Fourth year Nanoengineering with Electrical engineering focus undergraduate at UC San Diego. I am interested in the utilization of nanoengineering in medicine. Particularly the usage of Nanotechnology in targeted drug delivery, and cancer detection. My long term goals are being in the team which creates the first functioning nanosize robot, and obtaining a PhD in Nanoengineering . My hobbies are sleeping, rock climbing, and photography.

2017 Poster Presentation

2017 Research Abstract

Simultaneous Liposomal Encapsulation of FOLFIRINOX Chemotherapy Regimen

M.A. Ahmed, Department of NanoEngineering, University of California, San Diego, CA 92093
S. Correa, Department of Biological Engineering, Massachusetts Institute of Technology, MA 02139
A. Barberio, Department of Biological Engineering, Massachusetts Institute of Technology, MA 02139
P.T. Hammond, Department of Biological Engineering, Massachusetts Institute of Technology, MA 02139

Pancreatic cancer is considered one of the leading causes of cancer-related mortalities in the United States. According to the American Cancer Society (ACS), the one-year survival rate for all stages of pancreatic cancer is 20%. In 2017 alone, 43,090 of 53,670 newly diagnosed American patients will die from pancreatic cancer. The high mortality rate associated with this disease is due to the lack proper therapeutic options for patients diagnosed with it. FDA-approved three-drug chemotherapy regimen FOLFIRINOX, which is composed of CISPATIN/IRINOTECAN/FLUROROURCIL(5-FU) has shown to improve overall patient survival by 4 months compared to the GEMCITABINE chemotherapy alone. FOLFIRINOX has also shown to be one of most effective and promising regimens used for advanced metastatic pancreatic cancer patients today. However, significant toxicity is a limiting issue for this multi-drug regimen and only patients with good performance status are candidates to undergo the\is chemotherapy treatment. Recent developments in liposomal drug delivery systems have shown significant reduction in toxicity and side effects associated with FOLFIRINOX. For this study, a layer-by-layer modified liposomal drug delivery system was chosen for the simultaneous liposomal encapsulation, and systematic delivery of FOLFIRINOX chemotherapy regimen. This goal was achieved by asymmetrically functionalizing CISPLATIN with lipid tails1, and passively encapsulating IRITNOTECAN and FLUROROURCIL in the liposomal formulation composed of DSPC/DSPG/CHOLESTEROL (7:2:1 molar ratio).